The revolutionary global media channel for the pharmaceutical and biotech industry, PharmaTelevision, is celebrating its one year anniversary. Launched on May 18th 2006 and with viewing figures now averaging 8,000 per programme, the site is fast becoming one of the most popular channels for insight and intelligence across the industry.

The brainchild of PharmaVentures, a leading strategic advisory consultancy, based in Oxford, UK, the channel hosts weekly interviews with some of the industry’s key figures. Over the past year the CEO of PharmaVentures, Fintan Walton and his team have interviewed over 70 people including Rob Hockney, AstraZeneca, Eric de la Fortelle, Roche and Rob Wills, Johnson & Johnson.

Filmed at a variety of locations across the globe, including San Francisco, New York, Sydney and London’s Millbank Studios, the PharmaVentures Business Review programme examines trends and issues in the deals making arena. Each month, the programme covers a new therapeutic area or business related issue in the Month-in-Review, Business Report and Face-to-Face interview. These segments of the programme provide news on the key deals, discuss deal making trends, and give essential insight from industry experts.

Fintan Walton aims to expand and develop PharmaTelevision further in 2007, with the addition of new programmes and even more content. He comments “The industry is constantly changing and accessible mediums like these are essential to ensure busy people are up to speed and ahead of the game where possible. The site offers viewers the opportunity to gain valuable advice, position themselves as thought leaders and of course to showcase their business.

“PharmaTelevision is an exciting concept and the prospects for it are immense. We’d like to thank everyone who has supported us in its inaugural year and are calling for potential interviewees to contact us.”

A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. It provides tailored consulting services and adds value to deals through the PharmaDeals range of intelligence products which includes analysis tools, reports and workshops.

- ends -